Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126

Andrew M. McDonald; Lyudmila DeMora; Eddy S. Yang; John M. Hoyle; Andrew Lenzie; Grant R. Williams; Jeff M. Michalski; Don Yee; Jean Paul Bahary; Robert B. Den; Mack Roach; Robert Dess; Mark V. Mishra; Richard K. Valicenti; Harold Y. Lau; Samuel R. Marcrom; Luis Souhami; Lucas C. Mendez; Yuhchyau Chen; Desiree E. Doncals; Stephanie L. Pugh; Felix Y. Feng; Howard M. Sandler

doi:10.1002/cncr.34596

Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126

Andrew M. McDonald, Lyudmila DeMora, Eddy S. Yang, John M. Hoyle, Andrew Lenzie, Grant R. Williams, Jeff M. Michalski, Don Yee, Jean Paul Bahary, Robert B. Den, Mack Roach, Robert Dess, Mark V. Mishra, Richard K. Valicenti, Harold Y. Lau, Samuel R. Marcrom, Luis Souhami, Lucas C. Mendez, Yuhchyau Chen, Desiree E. DoncalsStephanie L. Pugh, Felix Y. Feng, Howard M. Sandler

Radiation Medicine

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Purpose: To validate the association between body composition and mortality in men treated with radiation for localized prostate cancer (PCa). Secondarily, to integrate body composition as a factor to classify patients by risk of all-cause mortality. Materials and Methods: Participants of NRG/Radiation Therapy Oncology Group (RTOG) 9406 and NRG/RTOG 0126 with archived computed tomography were included. Muscle mass and muscle density were estimated by measuring the area and attenuation of the psoas muscles on a single slice at L4–L5. Bone density was estimated by measuring the attenuation of the vertebral body at mid-L5. Survival analyses, including Cox proportional hazards models, assessed the relationship between body composition and mortality. Recursive partitioning analysis (RPA) was used to create a classification tree to classify participants by risk of death. Results: Data from 2066 men were included in this study. In the final multivariable model, psoas area, comorbidity score, baseline prostate serum antigen, and age were significantly associated with survival. The RPA yielded a classification tree with four prognostic groups determined by age, comorbidity, and psoas area. Notably, the classification among older (≥70 years) men into prognostic groups was determined by psoas area. Conclusions: This study strongly supports that body composition is related to mortality in men with localized PCa. The inclusion of psoas area in the RPA classification tree suggests that body composition provides additive information to age and comorbidity status for mortality prediction, particularly among older men. More research is needed to determine the clinical impact of body composition on prognostic models in men with PCa.

Original language	English
Pages (from-to)	685-696
Number of pages	12
Journal	Cancer
Volume	129
Issue number	5
DOIs	https://doi.org/10.1002/cncr.34596
State	Published - Mar 1 2023

Bibliographical note

Funding Information:
The authors thank the late Dr. James D. Cox of MD Anderson Cancer Center for his guidance and extensive work on the NRG/RTOG 9406 protocol design, development and his expertise in radiation oncology. This project was supported by grants U10CA180868 (NRG Oncology Operations), U10CA180822 (NRG Oncology SDMC), UG1CA189867 (NCORP), and U24CA180803 (IROC) from the National Cancer Institute (NCI).

Funding Information:
Felix Y. Feng reports consulting fees from Janssen, Bayer, PFS Genomics (termed April 2021), Myovant Sciences, Roivant Sciences, Astellas, Foundation Medicine, Varian, Bristol Meyers Squibb, Exact Sciences, and Novartis; receipt of stock options from Serimmune from serving on their scientific advisory board in 2020; and payment or honoraria from Bristol Meyers Squibb for two educational presentations. Dr. Feng reports his cofounder role at Artera, where he does not receive a salary, funding, or consulting fees from the company, only shares. He reports a leadership position with NRG Oncology, where he serves as the chair of the Genitourinary Cancer Committee. His role at NRG helps investigators design proposals for clinical trials that are then evaluated by the National Cancer Institute (NCI) for funding. All funding decisions are made by the NCI, not by NRG or by Dr. Feng. Mark V. Mishra reports support for attending meetings and/or travel from Varian Medical Systems. Howard M. Sandler reports consulting fees for his role as a member of the clinical trial steering committee for Janssen; he is also a member of the Board of Directors for ASTRO. Luis Souhami reports travel support from Varian Medical Systems and his participation on a Data Safety Monitoring Board or Advisory Board for AbbVie and Janssen. Grant R. Williams reports consulting fees from Cardinal Health and Carevive and payment or honoraria for presentations from Cardinal Health. Eddy S. Yang reports grants or contract from Eli Lilly and Puma Biotechnologies to UAB, and his participation on a Data Safety Monitoring Board or Advisory Board for AstraZeneca, Bayer, and Clovis. The other authors made no disclosures.

Publisher Copyright:
© 2022 American Cancer Society.

Keywords

anthropometry
body composition
clinical trials
mortality
muscle mass
prostate cancer

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/cncr.34596

Cite this

McDonald, A. M., DeMora, L., Yang, E. S., Hoyle, J. M., Lenzie, A., Williams, G. R., Michalski, J. M., Yee, D., Bahary, J. P., Den, R. B., Roach, M., Dess, R., Mishra, M. V., Valicenti, R. K., Lau, H. Y., Marcrom, S. R., Souhami, L., Mendez, L. C., Chen, Y., ... Sandler, H. M. (2023). Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126. Cancer, 129(5), 685-696. https://doi.org/10.1002/cncr.34596

@article{34a88c958d044eda8b7fc38970f02eb7,

title = "Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126",

abstract = "Purpose: To validate the association between body composition and mortality in men treated with radiation for localized prostate cancer (PCa). Secondarily, to integrate body composition as a factor to classify patients by risk of all-cause mortality. Materials and Methods: Participants of NRG/Radiation Therapy Oncology Group (RTOG) 9406 and NRG/RTOG 0126 with archived computed tomography were included. Muscle mass and muscle density were estimated by measuring the area and attenuation of the psoas muscles on a single slice at L4–L5. Bone density was estimated by measuring the attenuation of the vertebral body at mid-L5. Survival analyses, including Cox proportional hazards models, assessed the relationship between body composition and mortality. Recursive partitioning analysis (RPA) was used to create a classification tree to classify participants by risk of death. Results: Data from 2066 men were included in this study. In the final multivariable model, psoas area, comorbidity score, baseline prostate serum antigen, and age were significantly associated with survival. The RPA yielded a classification tree with four prognostic groups determined by age, comorbidity, and psoas area. Notably, the classification among older (≥70 years) men into prognostic groups was determined by psoas area. Conclusions: This study strongly supports that body composition is related to mortality in men with localized PCa. The inclusion of psoas area in the RPA classification tree suggests that body composition provides additive information to age and comorbidity status for mortality prediction, particularly among older men. More research is needed to determine the clinical impact of body composition on prognostic models in men with PCa.",

keywords = "anthropometry, body composition, clinical trials, mortality, muscle mass, prostate cancer",

author = "McDonald, {Andrew M.} and Lyudmila DeMora and Yang, {Eddy S.} and Hoyle, {John M.} and Andrew Lenzie and Williams, {Grant R.} and Michalski, {Jeff M.} and Don Yee and Bahary, {Jean Paul} and Den, {Robert B.} and Mack Roach and Robert Dess and Mishra, {Mark V.} and Valicenti, {Richard K.} and Lau, {Harold Y.} and Marcrom, {Samuel R.} and Luis Souhami and Mendez, {Lucas C.} and Yuhchyau Chen and Doncals, {Desiree E.} and Pugh, {Stephanie L.} and Feng, {Felix Y.} and Sandler, {Howard M.}",

note = "Funding Information: The authors thank the late Dr. James D. Cox of MD Anderson Cancer Center for his guidance and extensive work on the NRG/RTOG 9406 protocol design, development and his expertise in radiation oncology. This project was supported by grants U10CA180868 (NRG Oncology Operations), U10CA180822 (NRG Oncology SDMC), UG1CA189867 (NCORP), and U24CA180803 (IROC) from the National Cancer Institute (NCI). Funding Information: Felix Y. Feng reports consulting fees from Janssen, Bayer, PFS Genomics (termed April 2021), Myovant Sciences, Roivant Sciences, Astellas, Foundation Medicine, Varian, Bristol Meyers Squibb, Exact Sciences, and Novartis; receipt of stock options from Serimmune from serving on their scientific advisory board in 2020; and payment or honoraria from Bristol Meyers Squibb for two educational presentations. Dr. Feng reports his cofounder role at Artera, where he does not receive a salary, funding, or consulting fees from the company, only shares. He reports a leadership position with NRG Oncology, where he serves as the chair of the Genitourinary Cancer Committee. His role at NRG helps investigators design proposals for clinical trials that are then evaluated by the National Cancer Institute (NCI) for funding. All funding decisions are made by the NCI, not by NRG or by Dr. Feng. Mark V. Mishra reports support for attending meetings and/or travel from Varian Medical Systems. Howard M. Sandler reports consulting fees for his role as a member of the clinical trial steering committee for Janssen; he is also a member of the Board of Directors for ASTRO. Luis Souhami reports travel support from Varian Medical Systems and his participation on a Data Safety Monitoring Board or Advisory Board for AbbVie and Janssen. Grant R. Williams reports consulting fees from Cardinal Health and Carevive and payment or honoraria for presentations from Cardinal Health. Eddy S. Yang reports grants or contract from Eli Lilly and Puma Biotechnologies to UAB, and his participation on a Data Safety Monitoring Board or Advisory Board for AstraZeneca, Bayer, and Clovis. The other authors made no disclosures. Publisher Copyright: {\textcopyright} 2022 American Cancer Society.",

year = "2023",

month = mar,

day = "1",

doi = "10.1002/cncr.34596",

language = "English",

volume = "129",

pages = "685--696",

number = "5",

}

McDonald, AM, DeMora, L, Yang, ES, Hoyle, JM, Lenzie, A, Williams, GR, Michalski, JM, Yee, D, Bahary, JP, Den, RB, Roach, M, Dess, R, Mishra, MV, Valicenti, RK, Lau, HY, Marcrom, SR, Souhami, L, Mendez, LC, Chen, Y, Doncals, DE, Pugh, SL, Feng, FY & Sandler, HM 2023, 'Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126', Cancer, vol. 129, no. 5, pp. 685-696. https://doi.org/10.1002/cncr.34596

TY - JOUR

T1 - Body composition and mortality in men receiving prostate radiotherapy

T2 - A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126

AU - McDonald, Andrew M.

AU - DeMora, Lyudmila

AU - Yang, Eddy S.

AU - Hoyle, John M.

AU - Lenzie, Andrew

AU - Williams, Grant R.

AU - Michalski, Jeff M.

AU - Yee, Don

AU - Bahary, Jean Paul

AU - Den, Robert B.

AU - Roach, Mack

AU - Dess, Robert

AU - Mishra, Mark V.

AU - Valicenti, Richard K.

AU - Lau, Harold Y.

AU - Marcrom, Samuel R.

AU - Souhami, Luis

AU - Mendez, Lucas C.

AU - Chen, Yuhchyau

AU - Doncals, Desiree E.

AU - Pugh, Stephanie L.

AU - Feng, Felix Y.

AU - Sandler, Howard M.

N1 - Funding Information: The authors thank the late Dr. James D. Cox of MD Anderson Cancer Center for his guidance and extensive work on the NRG/RTOG 9406 protocol design, development and his expertise in radiation oncology. This project was supported by grants U10CA180868 (NRG Oncology Operations), U10CA180822 (NRG Oncology SDMC), UG1CA189867 (NCORP), and U24CA180803 (IROC) from the National Cancer Institute (NCI). Funding Information: Felix Y. Feng reports consulting fees from Janssen, Bayer, PFS Genomics (termed April 2021), Myovant Sciences, Roivant Sciences, Astellas, Foundation Medicine, Varian, Bristol Meyers Squibb, Exact Sciences, and Novartis; receipt of stock options from Serimmune from serving on their scientific advisory board in 2020; and payment or honoraria from Bristol Meyers Squibb for two educational presentations. Dr. Feng reports his cofounder role at Artera, where he does not receive a salary, funding, or consulting fees from the company, only shares. He reports a leadership position with NRG Oncology, where he serves as the chair of the Genitourinary Cancer Committee. His role at NRG helps investigators design proposals for clinical trials that are then evaluated by the National Cancer Institute (NCI) for funding. All funding decisions are made by the NCI, not by NRG or by Dr. Feng. Mark V. Mishra reports support for attending meetings and/or travel from Varian Medical Systems. Howard M. Sandler reports consulting fees for his role as a member of the clinical trial steering committee for Janssen; he is also a member of the Board of Directors for ASTRO. Luis Souhami reports travel support from Varian Medical Systems and his participation on a Data Safety Monitoring Board or Advisory Board for AbbVie and Janssen. Grant R. Williams reports consulting fees from Cardinal Health and Carevive and payment or honoraria for presentations from Cardinal Health. Eddy S. Yang reports grants or contract from Eli Lilly and Puma Biotechnologies to UAB, and his participation on a Data Safety Monitoring Board or Advisory Board for AstraZeneca, Bayer, and Clovis. The other authors made no disclosures. Publisher Copyright: © 2022 American Cancer Society.

PY - 2023/3/1

Y1 - 2023/3/1

N2 - Purpose: To validate the association between body composition and mortality in men treated with radiation for localized prostate cancer (PCa). Secondarily, to integrate body composition as a factor to classify patients by risk of all-cause mortality. Materials and Methods: Participants of NRG/Radiation Therapy Oncology Group (RTOG) 9406 and NRG/RTOG 0126 with archived computed tomography were included. Muscle mass and muscle density were estimated by measuring the area and attenuation of the psoas muscles on a single slice at L4–L5. Bone density was estimated by measuring the attenuation of the vertebral body at mid-L5. Survival analyses, including Cox proportional hazards models, assessed the relationship between body composition and mortality. Recursive partitioning analysis (RPA) was used to create a classification tree to classify participants by risk of death. Results: Data from 2066 men were included in this study. In the final multivariable model, psoas area, comorbidity score, baseline prostate serum antigen, and age were significantly associated with survival. The RPA yielded a classification tree with four prognostic groups determined by age, comorbidity, and psoas area. Notably, the classification among older (≥70 years) men into prognostic groups was determined by psoas area. Conclusions: This study strongly supports that body composition is related to mortality in men with localized PCa. The inclusion of psoas area in the RPA classification tree suggests that body composition provides additive information to age and comorbidity status for mortality prediction, particularly among older men. More research is needed to determine the clinical impact of body composition on prognostic models in men with PCa.

AB - Purpose: To validate the association between body composition and mortality in men treated with radiation for localized prostate cancer (PCa). Secondarily, to integrate body composition as a factor to classify patients by risk of all-cause mortality. Materials and Methods: Participants of NRG/Radiation Therapy Oncology Group (RTOG) 9406 and NRG/RTOG 0126 with archived computed tomography were included. Muscle mass and muscle density were estimated by measuring the area and attenuation of the psoas muscles on a single slice at L4–L5. Bone density was estimated by measuring the attenuation of the vertebral body at mid-L5. Survival analyses, including Cox proportional hazards models, assessed the relationship between body composition and mortality. Recursive partitioning analysis (RPA) was used to create a classification tree to classify participants by risk of death. Results: Data from 2066 men were included in this study. In the final multivariable model, psoas area, comorbidity score, baseline prostate serum antigen, and age were significantly associated with survival. The RPA yielded a classification tree with four prognostic groups determined by age, comorbidity, and psoas area. Notably, the classification among older (≥70 years) men into prognostic groups was determined by psoas area. Conclusions: This study strongly supports that body composition is related to mortality in men with localized PCa. The inclusion of psoas area in the RPA classification tree suggests that body composition provides additive information to age and comorbidity status for mortality prediction, particularly among older men. More research is needed to determine the clinical impact of body composition on prognostic models in men with PCa.

KW - anthropometry

KW - body composition

KW - clinical trials

KW - mortality

KW - muscle mass

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85145308033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85145308033&partnerID=8YFLogxK

U2 - 10.1002/cncr.34596

DO - 10.1002/cncr.34596

M3 - Article

C2 - 36579470

AN - SCOPUS:85145308033

VL - 129

SP - 685

EP - 696

IS - 5

ER -

Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this